PF4 Antibody Persistence and Long-term Pathogenicity in VITT
Anand Padmanabhan, Professor and Consultant at Mayo Clinic, shared on LinkedIn:
”Congrats to Adam Kanack, Emily Mauch, Guillaume Roberge, and coauthors related to their study on long-term persistence and pathogenicity of VITT antibodies.
Key points:
– Despite clonal restriction of Anti-PF4 abs in VITT, unlike MGTS, these monoclonal spikes are not seen when the entire IgG repertoire is examined. You unmask anti-PF4 clonal restriction only when you isolate the anti-PF4 antibodies
– In some cases, VITT abs can comprise kappa light chains (dogma to date is that it can only be lambda)
– As shown in a case in our report, thrombocytopenia can persist for more than 4 years.”
Read the full article here.
Title: Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia
Authors: Adam Kanack, Emily Mauch, Guillaume Roberge, Noah Splinter, Krishna Gundabolu, Geoffrey D. Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi J. Smock, David L. Green, Jonathan Coker, Mindy C. Kohlhagen, David L. Murray, Anand Padmanabhan
Keep up with Hemostasis Today.
-
Nov 29, 2025, 17:37Almahdi Ali Explores Ipsilateral Paradoxical Thromboembolism at 22nd European Angiology Days 2025
-
Nov 29, 2025, 17:23Jack Shuang Hou Shares Major Neurology Updates This Week
-
Nov 29, 2025, 16:52Federica Fogacci on Further Strengthening Collaboration Within the Lp(a)CCELERATE Study
-
Nov 29, 2025, 16:42Dr Abdul Mannan on the Echinocyte: Mastering the Diagnostic Duality of Artifact vs. Pathology
-
Nov 29, 2025, 16:42Vikas Dua: Heme Next 1.0 A Conference with a Difference
-
Nov 29, 2025, 16:41Hind Ali: Sources Of Error in Cell Counts
-
Nov 29, 2025, 16:40Maxime Dely: Even on a Break, You Can Give
-
Nov 29, 2025, 16:39Shrinidhi Nathany: HemeNext Brings Science, Technology, and Leadership Together
-
Nov 29, 2025, 16:37Thrombopoiesis Simplified: Omar Adwan on How Platelets Are Made